IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the...
Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development...
Infant Bacterial Therapeutics AB (publ) today announced that Marie-Louise Alamaa has been appointed Chief Financial Officer (CFO) effective from August...
Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during...
CEO Staffan Strömberg's speech at the Annual General Meeting of IBT is available here. The speech is in Swedish. About Infant Bacterial Therapeutics...
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: About Infant Bacterial...
Message from the CEO IBT is conducting a phase III-study (“The Connection Study”) which is the last phase of the clinical development program...
After the Data Monitoring Committees’ review Infant Bacterial Therapeutics expands the enrollment criteria of The Connection Study to include 500...
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application...
Infant Bacterial Therapeutics AB (publ) has today published the Annual Report for 2020. The report is available on IBT’s website ibtherapeutics.com...

Subscribe to our press releases